
Sign up to save your podcasts
Or


As the CEO of medical technology company ZELTIQ, Mark Foley was on the front lines of a major business transformation. Venrock's Bryan Roberts talks to Foley about turning the company around by changing the business model and swapping out the majority of leadership, culminating in the successful acquisition by Allergan for $2.4 billion in April 2017. But the exit wasn't all smooth sailing. Foley shares details on the initial failed bids that rocked the company's culture, how he managed morale during this tricky time, and what led to the successful deal in the end. He also shares how investors can recover after an initial stumble, and how he made the transition from VC to CEO successfully.
By Venrock, a venture capital firm4.8
6262 ratings
As the CEO of medical technology company ZELTIQ, Mark Foley was on the front lines of a major business transformation. Venrock's Bryan Roberts talks to Foley about turning the company around by changing the business model and swapping out the majority of leadership, culminating in the successful acquisition by Allergan for $2.4 billion in April 2017. But the exit wasn't all smooth sailing. Foley shares details on the initial failed bids that rocked the company's culture, how he managed morale during this tricky time, and what led to the successful deal in the end. He also shares how investors can recover after an initial stumble, and how he made the transition from VC to CEO successfully.

1,289 Listeners

2,672 Listeners

2,444 Listeners

1,100 Listeners

341 Listeners

324 Listeners

394 Listeners

5,526 Listeners

9,901 Listeners

34 Listeners

505 Listeners

19 Listeners

263 Listeners

517 Listeners

1,354 Listeners